Kazia Therapeutics shares are trading lower after the company announced a proposed public offering.

Kazia Therapeutics Commences Offering Of American Depositary Shares; Terms Undisclosed

Kazia Therapeutics Limited (NASDAQ:KZIA) ("Kazia" or the "Company"), an oncology-focused biotechnology company developing therapies that selectively reprogram cancer biology, restore anti-tumor immunity

Kazia Therapeutics Says Paxalisib Phase 1b Data In Six Evaluable Stage IV Triple-Negative Breast Cancer Patients Showed 83% Objective Response Rate, No Treatment-Related Serious Adverse Events

Canaccord Genuity Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $29

Canaccord Genuity analyst John Newman initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $29.